Neovasc (NASDAQ:NVCN) Shares Up 1.1%

Neovasc Inc (NASDAQ:NVCN) (TSE:NVC) shares shot up 1.1% on Monday . The stock traded as high as $2.97 and last traded at $2.80, 525 shares traded hands during trading. A decline of 100% from the average session volume of 186,427 shares. The stock had previously closed at $2.77.

Several research firms recently weighed in on NVCN. Zacks Investment Research cut shares of Neovasc from a “buy” rating to a “hold” rating in a research note on Friday, July 12th. ValuEngine raised shares of Neovasc from a “hold” rating to a “buy” rating in a research note on Tuesday, July 2nd.

The firm has a market capitalization of $20.72 million, a price-to-earnings ratio of -0.11 and a beta of 1.41. The company has a 50 day simple moving average of $2.75.

Neovasc (NASDAQ:NVCN) (TSE:NVC) last issued its quarterly earnings data on Thursday, May 9th. The medical equipment provider reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.13). The business had revenue of $0.59 million for the quarter, compared to analyst estimates of $0.40 million. On average, equities research analysts predict that Neovasc Inc will post -6 EPS for the current year.

A hedge fund recently bought a new stake in Neovasc stock. Wedbush Securities Inc. purchased a new position in shares of Neovasc Inc (NASDAQ:NVCN) (TSE:NVC) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 126,000 shares of the medical equipment provider’s stock, valued at approximately $53,000. Wedbush Securities Inc. owned 0.20% of Neovasc at the end of the most recent quarter. Institutional investors and hedge funds own 9.98% of the company’s stock.

Neovasc Company Profile (NASDAQ:NVCN)

Neovasc Inc, a specialty medical device company, develops, manufactures, and markets cardiovascular devices worldwide. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company also provides Peripatch tissue products.

Recommended Story: Insider Trading – What You Need to Know

Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with MarketBeat.com's FREE daily email newsletter.